Long-term impact of secondary preventive treatments in patients with stable angina

European Journal of Epidemiology

Volumn 26, Issue 5, 2011, Pages 375-383

  Vokó, Zoltán ^a   De Brouwer, Sophie ^b   Lubsen, Jacobus ^b,f   Danchin, Nicolas ^c   Otterstad, Jan Erik ^d   Dunselman, Peter H J M ^e   Kirwan, Bridget Anne ^b  

^a EÖTVÖS LORÁND UNIVERSITY   (Hungary)

^b SOCAR RESEARCH SA   (Switzerland)

^c HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^d VESTFOLD HOSPITAL TRUST   (Norway)

^e AMPHIA HOSPITAL   (Netherlands)

^f ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Angina pectoris; Cardiovascular agents; Coronary artery bypass; Coronary disease; G estimation; Percutaneous coronary intervention; Secondary prevention

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NIFEDIPINE; PLACEBO;

AGED; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DRUG EFFICACY; FEMALE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; SECONDARY PREVENTION; STABLE ANGINA PECTORIS; STROKE; SURVIVAL TIME;

ANGINA PECTORIS; ANGIOPLASTY, BALLOON, CORONARY; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOVASCULAR AGENTS; CAUSE OF DEATH; CORONARY ARTERY BYPASS; CORONARY DISEASE; FEMALE; HUMANS; HYPOLIPIDEMIC AGENTS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; SECONDARY PREVENTION; TREATMENT OUTCOME;

EID: 79959737713     PISSN: 03932990     EISSN: 15737284     Source Type: Journal    
DOI: 10.1007/s10654-011-9558-5     Document Type: Article

References (18)

1. Kjekshus J, Apetrei E, Barrios V, Böhm M, Cleland JG, Cornel JH, Dunselman P, Fonseca C, Goudev A, Grande P, Gullestad L, Hjalmarson A, Hradec J, Jánosi A, Kamenský G, Komajda M, Korewicki J, Kuusi T, Mach F, Mareev V, McMurray JJ, Ranjith N, Schaufelberger M, Vanhaecke J, van Veldhuisen DJ, Waagstein F, Wedel H, Wikstrand J. CORONA Group. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007;357:2248-61. (Pubitemid 350190755)
2. Poole-Wilson PA, Lubsen J, Kirwan BA, van Dalen FJ, Wagener G, Danchin N, Just H, Fox KA, Pocock SJ, Clayton TC, Motro M, Parker JD, Bourassa MG, Dart AM, Hildebrandt P, Hjalmarson A, Kragten JA, Molhoek GP, Otterstad JE, Seabra-Gomes R, Soler-Soler J, Weber S. Coronary disease Trial Investigating Outcome with Nifedipine gastrointestinal therapeutic system investigators. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet. 2004;364:849-57.
3. Lubsen J, Poole-Wilson PA, Pocock SJ, van Dalen FJ, Baumann J, Kirwan BA, Parker AB. Design and current status of ACTION: A Coronary disease Trial Investigating Outcome with Nifedipine GITS. Gastro-Intestinal Therapeutic System. Eur Heart J. 1998;19(I):I20-32.
4. Management of stable angina pectoris. Recommendations of the Task Force of the European Society of Cardiology. Eur Heart J. 1997;18(3):394-413.
5. Dalal H, Evans PH, Campbell JL. Recent developments in secondary prevention and cardiac rehabilitation after acute myocardial infarction. Br Med J. 2004;328:693-7. (Pubitemid 38393412)
6. Fox K, Garcia MA, Ardissino D, Buszman P, Camici PG, Crea F, Daly C, De Backer G, Hjemdahl P, Lopez-Sendon J, Marco J, Morais J, Pepper J, Sechtem U, Simoons M, Thygesen K, Priori SG, Blanc JJ, Budaj A, Camm J, Dean V, Deckers J, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Tamargo J, Zamorano JL. Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology; ESC Committee for Practice Guidelines (CPG). Guidelines on the management of stable angina pectoris: executive summary: the Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J. 2006;27:1341-81.
7. Kirwan BA, Lubsen J, Poole-Wilson PA. Treatment of angina pectoris: associations with symptom severity. Int J Cardiol. 2005;98:299-306. (Pubitemid 40431178)
8. Kirwan BA, Lubsen J, Brouwer S, Danchin N, Battler A, Bayes de Luna A, Dunselman PH, Glasser S, Koudstaal PJ, Sutton G, van Dalen FJ, Poole-Wilson PA. ACTION (A Coronary disease Trial Investigating Outcome with Nifedipine GITS) investigators. Diagnostic criteria and adjudication process both determine published event-rates: The ACTION trial experience. Contemp Clin Trials. 2007;28:720-9.
9. Mark SD, Robins JM. Estimating the causal effect of smoking cessation in the presence of confounding factors using a rank preserving structural failure time model. Stat Med. 1993;12: 1605-28. (Pubitemid 23269291)
10. Sterne JAC, Tilling K. G-estimation of causal effects, allowing for time-varying confounding. Stata J. 2002;2:164-82.
11. Filippi A, Gensini G, Bignanimi AA, Sabatini A, Mazzaglia G, Cricelli C. Management of patients with suspected angina, but without known myocardial infarction: a cross-sectional survey. Br J Gen Pract. 2004;54:429-33. (Pubitemid 38771888)
12. Hemingway H, McCallum A, Shipley M, Manderbacka K, Martikainen P, Keskimaki I. Incidence and prognostic implications of stable angina pectoris among women and men. JAMA. 2006;295:1404-11.
13. Gibbons RJ, Abrams J, Chatterjee K, Daley J, Deedwania PC, Douglas JS, Ferguson TB Jr, Fihn SD, Fraker TD Jr, Gardin JM, O'Rourke RA, Pasternak RC, Williams SV. American College of Cardiology; American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina). ACC/AHA 2002 guideline update for the management of patients with chronic stable angina-summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina). J Am Coll Cardiol. 2003;41:159-68.
14. Daly C, Clemens F, Lopez-Sendon JL, Tavazzi L, Boersma E, Danchin N, Delahaye F, Gitt A, Julian D, Mulcahy D, Ruzyllo W, Thygesen K, Verheugt F. Fox KM; Euro Heart Survey Investigators. The impact of guideline compliant medical therapy on clinical outcome in patients with stable angina: findings from the Euro Heart Survey of stable angina. Eur Heart J. 2006;27: 1298-304.
15. Danchin N, Cambou JP, Hanania G, Kadri Z, Genes N, Lablanche JM, Blanchard D, Vaur L, Clerson P. Guéret P; USIC 2000 investigators. Impact of combined secondary prevention therapy after myocardial infarction: data from a nationwide French registry. Am Heart J. 2005;150:1147-53.
16. Miettinen OS. The need for randomization in the study of intended effects. Stat Med. 1983;2:267-71. (Pubitemid 13020139)
17. Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med. 2002;347:969-74.
18. Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356:1503-16. (Pubitemid 46588415)